Which of the following is part of the empiric treatment for an inpatient adult with CAP?

The correct answer is based on the fact that empiric treatment for community-acquired pneumonia (CAP) in hospitalized adults often includes broad-spectrum coverage for the most common pathogens. Augmentin, which combines amoxicillin with clavulanate, and cefpodoxime are both effective second-line options that provide coverage against organisms like Streptococcus pneumoniae and Haemophilus influenzae, which are frequently responsible for CAP.

In an inpatient setting, especially when risks for resistant organisms exist or when the patient may have significant comorbidities, a combination of beta-lactams and other agents may be employed. Augmentin, in particular, also provides coverage against beta-lactamase-producing bacteria, making it a suitable choice in this scenario.

The other options may offer some level of coverage, but they may not be appropriate as monotherapy or may not encompass the spectrum of pathogens as effectively as the beta-lactam combination presented in the correct choice. For instance, doxycycline can be effective, but it is typically considered in outpatient settings or for atypical coverage rather than as empiric treatment for a hospitalized adult with CAP.